ArticleFrontiers in oncology2025
HALP score as a prognostic marker for overall survival in advanced pancreatic cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The HALP score is a novel prognostic biomarker in multiple myeloma: A retrospective cohort study of 450 patients.Medicine · 2026Article
- Comparative Prognostic Performance of HALP, PIV, and Naples Prognostic Score in Critically Ill Patients with Sepsis: A Retrospective Multicentre Cohort Study.Journal of clinical medicine · 2026Article
- Preoperative HALP Score as a Marker of Tumor Aggressiveness and Survival in Surgically Treated Soft Tissue Sarcoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Prognostic value of the HALP score in patients with testicular cancer: a retrospective study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Predictive Value of the Cally Score in Determining Surgical Strategy for Complicated Left-Sided Colonic Diverticulitis: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic cancer is the leading cause of cancer-related deaths worldwide and most of the patients diagnosed at an advanced stage. Clinicians need simple, effective, and repeatable tools to predict the prognosis. This study aimed to evaluate the relationship between the HALP score and prognosis in patients with advanced pancreatic cancer. Methods: Patients diagnosed with advanced pancreatic cancer at three centers in Turkey between 2009 and 2023 were included in this retrospective study. Demographic features, blood parameters, treatment received, treatment responses, and survival were recorded. Results: 227 patients were included in the study. The median overall survival (OS) for the entire cohort was 10.4 months. The median OS was 8.7 months in the low-HALP group and 11.2 months in the high- HALP group. Patients in the low-HALP group had a significantly shorter median OS than those in the high-HALP group (log rank p=0.001). Conclusion: The HALP score is a reliable and practical tool that can be utilized in clinical practice to predict prognosis in patients with advanced pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.